Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa

Current Drug Metabolism

Volumn 12, Issue 1, 2011, Pages 51-56

  Fehintola, Fatai A ^a   Akinyinka, Olusegun O ^a   Adewole, Isaac F ^b   Maponga, Chiedza C ^c   Ma, Qing ^d   Morse, Gene D ^c  

^a Department of Pharmacology and Therapeutics ^*  (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Chemoprophylaxis; Drug interactions; HIV infection; Malaria; Sub Saharan Africa

Indexed keywords

ABACAVIR; AMODIAQUINE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMETHER; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; COTRIMOXAZOLE; DIDANOSINE; DIHYDROARTEMISININ; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; MARAVIROC; MEFLOQUINE; NEVIRAPINE; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; PYRONARIDINE; QUININE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

AFRICA; AGRANULOCYTOSIS; ANTIMALARIAL DRUG RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIVER TOXICITY; MALARIA; MIXED INFECTION; PRURITUS;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; ANTIMALARIALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG RESISTANCE; HIV INFECTIONS; HUMANS; MALARIA;

EID: 79951589957     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011794520008     Document Type: Article

References (47)

1. WHO. 2008. World Health Statistics 2008: Mortality and burden of disease. Geneva: WHO, 2008; pp. 36-64.
2. Bryce J, Bosch-Pinto C, Black RE. WHO estimates of the causes of death in children. Lancet. 2005, 365(6465), 1147-1152. (Pubitemid 40417564)
3. Black RE, Morris SS. Where and why 10 million children dying every year? Lancet, 2003, 361(9376), 2226-2234 (Pubitemid 36782560)
4. Spencer, H. C., Drug-resistant malaria: Changing patterns mean difficult decisions. Trans. R. Soc. Trop. Med. Hyg., 1985, 79, 748-758. (Pubitemid 16201807)
5. Wernsdorfer WH. The development and spread of resistant malaria. Parasitology Today. 1991, 7, 297-303.
6. World Health Organization. 2001. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. WHO/CDS/RBM/2001, 35, Geneva: WHO.
7. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December 2006. Available at: http://data.unaids.org/pub/EpiReport/2006/2006-EpiUpdate-en.pdf Accessed March 12 2007.
8. Murphy EL, Collier AC, Kalish SA, Assmann SF, Para MF, Flanigan PT, Kumar PN, Mintz L, Wallach MR, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 2001, 135, 17-26. (Pubitemid 32619279)
9. WHO. WHO Guidelines for treatment of malaria. WHO/HTM/MAL/2006.1108.
10. French, N.; Nakiyingi, J.; Lugada, E.; Watera, C.; Whitworth, J. A.; Gilks, C. F. Increasing rate of malarial fever with deteriorating immune status in HIV-1 infected Ugandan adults. AIDS, 2001, 15, 899-906. (Pubitemid 32424393)
11. Whitworth, J.; Morgan, D.; Quigley, M. Effect of HIV and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: A cohort study. Lancet, 2000, 356, 1051-1056.
12. Ajayi, I. O.; Falade, C. O. Pre-hospital treatment of febrile illness in children attending the General Outpatients Clinic, University College Hospital, Ibadan, Nigeria. Afr J Med Med Sci. 2006, 35, 85-91.
13. Fehintola FA. Pre-hospital and prescription use of antibacterial drugs at a secondary health centre in Ibadan, Nigeria. Afr. J. Pharmacy Pharmacol., 2009, (In press).
14. Olatunde, A.; Obih, P. O. Use and misuse of 4-aminoquinoline antimalarials in tropical Africa and re-examination of itch reaction to these drugs. Tropical Doctor, 1981, 11, 97-101. (Pubitemid 11048573)
15. Nigeria Federal Ministry of Health National Antimalarial Treatment Policy, Abuja 2004.
16. Fogh, S.; Jepsen. S.; Effersoe. P. Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans. R. Soc. Trop. Med. Hyg., 1979, 73, 228-229. (Pubitemid 9159413)
17. D'Alessandro, U.; Buttiens, H. History and importance of antimalarial drug resistance. Trop. Med. Int. Health, 2001, 6, 845-848. (Pubitemid 33010869)
18. Nuwaha, F. The challenge of chloroquine-resistant malaria in sub Saharan Africa. Health Policy Plan., 2001, 16, 1-12. (Pubitemid 32183642)
19. Fehintola, F. A.; Adedeji, A. A.; and Sowunmi, A. Comparative efficacy of chloroquine and cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children. Cent. Afr. J. Med., 2002, 48, 101-105.
20. Bloland, P. B.; Redd, S. C.; Kazembe, P.; Tembenu, R.; Wirima, J. J.; Campbell, C. C. Cotrimoxazole for childhood febrile illness in malaria endemic regions. Lancet, 1991, 337, 518-520.
21. Ter Kuile, F. O.; Van Eijk, A. M.; Filler, S. J. Effect of sulpahdoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. A systematic review. JAMA, 2007, 297, 2603-2616. (Pubitemid 46961032)
22. Menendez, C.; D'Alessandro, U.; Ter Kuile, F. O. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect. Dis., 2007, 7, 126-135. (Pubitemid 46137946)
23. World Health Organization. The World Health Report 1999: Making a difference. World Health Organization, Geneva, 1999.
24. Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434, 214-217. (Pubitemid 40388051)
25. Krogstad DJ, Gluzman IY, Kyle DE, Oduola AMJ, Martin SK, Milhous WK, Schlesinger, P. H. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science, 1987, 238, 1283-1285.
26. Martin, S. K.; Oduola, A. M. J.; Milhous, W. K. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science, 1987;235, 899-901 (Pubitemid 17019130)
27. Sowunmi, A.; Oduola, A. M. J.; Ogundahunsi, O. A. T. Enhanced efficacy of chloroquine/chlorpheniramine combination in acute uncomplicated falciparum malaria in children. Trans. R. Soc. Trop. Med. Hyg. 1997, 91, 63-67. (Pubitemid 27095504)
28. Sowunmi, A.; Fehintola, F. A.; Ogundahunsi, O. A. T.; Oduola, A. M. J. Comparative efficacy of chlorquine plus chlorpheniramine and halofantrine in acute uncomplicated falciparum malaria in Nigerian children. Trans. R. Soc. Trop. Med. Hyg. 1998, 92, 441-445. (Pubitemid 28409897)
29. Krishna, S.; White, N. J. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet., 1996, 30, 263-299.
30. He, Z.; Qin, L.; Chen, L.; Peng, N.; You, J.; Chen. X. Synergy of Human Immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and plasmodium chabaudi in vivo. Antimicrob Agents Chemother, 2008, 52, 2653-2656. (Pubitemid 351915702)
31. Winstanley, P. A.; Coleman, J. W.; Maggs. J. M.; Breckenridge, A. M, Park, B. K. The toxicity of amodiaquine and its principal metabolites towards mononuclear leukocytes and granulocytemonocyte colony forming units. Br. J. Clin. Pharmacol., 1990, 29, 479-485. (Pubitemid 20134159)
32. German, P.; Greenhouse, B.; Coates, C.; Dorsey, G.; Rosenthal, P. J, Charlebois E, Lindegardh, N, Havlir, D, Aweeka, FT. Hepatotoxicity due to interaction between artesunate plus amodiaquine and efavirenz. Clin. Infect. Dis., 2007, 44, 889-891. (Pubitemid 46365323)
33. Mockenhaupt, F. P. Mefloquine resistance in Plasmodium falciparum. Parasitology Today, 1995, 11, 248-253.
34. Lobel, H. O.; Varma, J. K.; Miani, M.; Green, M.; Todd. GD, Grady, K.; Barber, A. M. Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: Implications for travellers' health. Am. J. Trop. Med. Hyg., 1998, 59, 129-132. (Pubitemid 28304809)
35. White N. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R. Soc. Lond. B, 1999, 354, 739-749. (Pubitemid 29365622)
36. White, N. J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans. R. Soc. Med. Hyg., 1994, 88 (suppl 1), 41-43. (Pubitemid 124018824)
37. Khoo, S.; Back, D.; Winstanley, P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 2005, 19, 995-1005. (Pubitemid 40961139)
38. Sousa, M.; Pozniak, A.; Boffito, M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarials. J. Antimicrob. Chemother., 2008, 62, 872-878.
39. Nasta, P.; Gulletta, M.; Busi, G.; Tedoldi, S.; Saleri, N.; Matteelli, A. Fatal falciparum malaria in an HIV infected traveller. Int. Conf. AIDS, 2002, Jul. 7-12, 14, Abstract no TuPeE5219.
40. Ezzet, F.; Van Vugt, M.; Nosten, F.; Looareesuwan, S.; White, N. J. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother., 2000, 44, 697-704. (Pubitemid 30117964)
41. Vallely, A.; Vallely, L.; Changalucha, J.; Greenwood, B.; Chandramohan, D. Intermittent preventive treatment for malaria in pregnancy for Africa: What's new, what's needed?. Malaria J. 2007, 6, 1-13.
42. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV1 infected adults and adolescents. Department of Health and Human Services. November 3, 2008:1-139. Available at: http://aidsinfo.nih.gov/contentFiles/AdultandAdolescentGL.pdf. Accessed date: April 6, 2009.
43. Skinner-Adams, T. S.; McCarthy, J. S.; Gardiner, D. L.; Hilton, P. M.; Andrews, K. T. Antiretrovirals as antimalarial agents. J. infect. Dis., 2004, 190, 1998-2000. (Pubitemid 39564706)
44. Maponga, C. C.; Ma, Q.; Slish, J. C.; Morse, G. D. HIV pharmacotherapy issues, challenges, and priorities in sub Saharan African countries. Top. HIV Med., 2007, 19, 104-110.
45. Nantulya, F. N.; Kengeya-Kayondo J. F.; Ogundahunsi, O. A. T. Research themes and advances in malaria research capacity made by Multilateral Initiative on Malaria. Am. J. Trop. Med. Hyg., 2007, 77 (Suppl 6), 303-313.
46. Kerb, R, Fux, R, Mörike, K.; Kremsner, P. G.; Gil. J. P.; Gleiter, C, H.;, Schwab M. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet. Infect. Dis., 2009, 9, 760-774.
47. Ma, Q.; Okusanya, O. O.; Smith, P. F.; Dicenzo, R.; Slish, J. C.; Catanzaro, L. M.; Forrest, A.; Morse, G. D. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert. Opin. Drug. Metab. Toxicol., 2005, 1, 473-485.